2334 results about "Stereoselectivity" patented technology

The present invention provides compositions comprising metal complexes, and related methods. In some embodiments, metal complexes of the invention may be useful as catalysts for chemical reactions, including metathesis reactions, wherein the catalysts exhibit enhanced activity and stereoselectivity. In some embodiments, the invention may advantageously provide metal complexes comprising a stereogenic metal atom. Such metal complexes may be useful in enantioselective catalysis.

The radiolabeled non-natural amino acid 1-amino-3-cyclobutane-1-carboxylic acid (ACBC) and its analogs are candidate tumor imaging agents useful for positron emission tomography and single photon emission computed tomography due to their selective affinity for tumor cells. The present invention provides methods for stereo-selective synthesis of syn-ACBC analogs. The disclosed synthetic strategy is reliable and efficient and can be used to synthesize a gram quantity of various syn-isomers of the ACBC analogs, particularly, syn-[¹⁸F]-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC) and syn-[¹²³I]-1-amino-3-iodocyclobutane-1-carboxylic (IACBC) acid analogs.

The invention provides a method for screening stereoselective alpha-hydroxy acid dehydrogenase, comprising the following steps: (1) dissolving a sample to be detected containing alpha-hydroxy acid dehydrogenase in a buffer with pH of 6-9, adding an alpha-hydroxy acid chiral monomer as a substrate, and carrying out conversion reaction in water-bath at 20-50 DEG C; and (2) after the conversion reaction, adding the conversion solution in an FeCl3 developer solution to conduct color development reaction for 5-30 min, when the color development reaction finishes, judging the result according to the color appeared in the reaction solution. The method has no need to carry out derivatization on the substrate which is intend to screen, can rapidly identify the dehydrogenase activity and optical selectivity of the selected microbe by using simple colourimetry, has the advantages of simple screening flow, fast speed, low request for devices, strong versatility and the like, and offers great conveniences to the obtainment of optically pure products by using racemic mandelic acid and related derivatives as substrates to carry out resolution through biological enzymatic method.

The present invention is directed to an improved synthesis of clasto-lactacystin-β-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-β-lactones, and analogs thereof and their use as proteasome inhibitors.

Glutamic acid derivatives, in particular monatin, may be conveniently prepared by alkylating a 4-protected hydroxyl pyroglutamic acid derivative with an alkylating agent to prepare a 4-protected hydroxyl-4-alkylglutamic acid derivative, followed by the steps of hydrolysis and deprotection. The 4-protected hydroxyl pyroglutamic acid derivative is easy to produce from hydroxyproline. The 4-protected hydroxyl pyroglutamic acid derivative is particularly suitable for use in the efficient manufacture of monatin of high optical purity, since it can be alkylated selectively at the 4-position and stereoselectively and after its alkylation, it can easily be converted to a glutamic acid derivative.

Intermediate compounds in the synthesis of Sitagliptin, 3-amino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester, and amino protected-3-amino-4-(2,4,5-trifluorophenyl)but-2-enoic acid alkyl ester, and the stereoselective reduction of these compound to give Synthon I, or the amino-protected Synthon I, are provided.

The present invention provides a method for manufacturing polycarbonate, which has a high conversion rate of a propylene oxide material into a polymer and can control stereoregularity of the macromolecular structure, and a catalytic compound for the manufacturing method.

The manufacturing method of the present invention is a method for manufacturing a polycarbonate copolymer by copolymerizing an epoxide compound as a monomer with carbon dioxide in the presence of a planar tetracoordinate-type cobalt-Schiff base complex, wherein a ligand of the Schiff base is N,N′-bis(2-hydroxybenzylidene)ethylenediamine, N,N′-bis(2-hydroxybenzylidene)phenylenediamine, or a derivative thereof, and a methyl group substituted with an amino group having an asymmetrical carbon atom or an asymmetrical axis is introduced to the 3- and/or 3′-position of the benzene ring derived from the salicyl group. In addition, the catalytic compound of the present invention is a cobalt-Schiff base complex, wherein a methyl group substituted with an amino group having an asymmetrical carbon atom or an asymmetrical axis is introduced to the 3- and/or 3′-position of the salicyl group.

Methods and compositions are disclosed to engineer plastids comprising heterologous genes encoding immuno-activating domains fused to an extracellular domain (ECD) of a receptor or surface glycoprotein, a growth factor or an enzyme and produced within a subcellular organelle, such as a chloroplast. The immuno-activating domains may include those regions of a protein capable of modulating the interaction between immune effector cells via proteins containing stereoselective binding domains and specific ligands, such as the Fc regions of antibodies. The present disclosure also demonstrates the utility of plants, including green algae, for the production of complex multi-domain fusion proteins as soluble bioactive therapeutic agents.

The present invention relates to halocarbon and halohydrocarbon chemistry, including methods of dehalogenating halocarbons and halohydrocarbons to provide, inter alia, alcohols, polyols, and epoxides. In general, the methods involve reaction pathways catalyzed by altered hydrolase enzymes that can provide stereoselective or stereospecific reaction products. The invention also includes methods of providing altered nucleic acids that encode altered dehalogenase or other hydrolase enzymes. Additionally, the invention includes various reaction formats and kits.

A process for the catalytic hydrogenation of an organic compound, in particular a labile organic compound, in the presence of a support catalyst with a coating containing ruthenium as active metal and a total of 1.01 to 30 wt. % of active metals. Higher stereoselectivity and a greater catalyst shelf life may be obtained by using a support catalyst of which the oxide, carbide, nitride or siliceous support material has a BET (N2) surface area smaller than 10 m2/g, particularly preferably 0.1 to 5 m2/g, prior to loading with at least one active metal diatomaceous earth with a BET (N2) surface area greater than 2 m2/g is excluded and the ruthenium content thereof makes up at least 50 wt. %, preferably at least 99 wt. % of the active metals. The process and the catalysts are particularly suitable for the hydrogenation of polyfunctional compounds such as hydroxycarbonyl compounds and aromatic amines.

Stereoselective and regioselective synthesis of compounds via nucleophilic ring opening reactions of aziridinium ions for use in stereoselective and regioselective synthesis of therapeutic and diagnostic compounds.

This invention discloses a method for preparing 4, 4'-diamino dicyclohexylmethane (H12MDA) from 4, 4'-diamino diphenylmethane (MDA) via hydrogenation catalyzed by supported nanoscale Ru catalyst. The method comprises: performing stereoselective hydrogenation on MDA at 100-180 deg.C and 4-10 MPa in an intermittent autoclave for 1-9 h to obtain H12MDA. The MDA conversion rate is near 100%, the H12MDA weight yield is near 100%, and the trans-H12MDA content is below 25%. After the supported nanoscale Ru catalyst is continuously reused for above 30 times without supplementation, the MDA conversion rate is still near 100%, and the trans-H12MDA content is below 27%.

A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.